KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Common Equity (2020 - 2025)

Organon has reported Common Equity over the past 6 years, most recently at $752.0 million for Q4 2025.

  • Quarterly results put Common Equity at $752.0 million for Q4 2025, up 59.32% from a year ago — trailing twelve months through Dec 2025 was $752.0 million (up 59.32% YoY), and the annual figure for FY2025 was $752.0 million, up 59.32%.
  • Common Equity for Q4 2025 was $752.0 million at Organon, down from $906.0 million in the prior quarter.
  • Over the last five years, Common Equity for OGN hit a ceiling of $4.7 billion in Q1 2021 and a floor of -$1.9 billion in Q2 2021.
  • Median Common Equity over the past 5 years was -$312.5 million (2023), compared with a mean of -$127.2 million.
  • Biggest five-year swings in Common Equity: tumbled 127.61% in 2021 and later surged 1029.17% in 2025.
  • Organon's Common Equity stood at -$1.5 billion in 2021, then soared by 40.85% to -$892.0 million in 2022, then skyrocketed by 92.15% to -$70.0 million in 2023, then skyrocketed by 774.29% to $472.0 million in 2024, then surged by 59.32% to $752.0 million in 2025.
  • The last three reported values for Common Equity were $752.0 million (Q4 2025), $906.0 million (Q3 2025), and $733.0 million (Q2 2025) per Business Quant data.